PDS Biotech Announces Updated Data From The IMMUNOCERV Phase 2 Clinical Trial Evaluating Versamune HPV With Chemoradiation To Treat Locally Advanced Cervical Cancer Will Be Presented During An Oral Presentation At The 2024 Astro Annual Meeting
PDS Biotech Announces Updated Data From The IMMUNOCERV Phase 2 Clinical Trial Evaluating Versamune HPV With Chemoradiation To Treat Locally Advanced Cervical Cancer Will Be Presented During An Oral Presentation At The 2024 Astro Annual Meeting
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune HPV (formerly PDS0101) with chemoradiation to treat locally advanced cervical cancer will be presented during an oral presentation at the 2024 ASTRO Annual Meeting being held in Washington, DC, and virtually September 29 through October 2, 2024.
普迪思生物技术公司（纳斯达克股票代码：PDSB）（“PDS Biotech”或“公司”）是一家专注于改变免疫系统如何靶向和杀死癌症及开发感染病疫苗的后期免疫疗法公司。今天宣布，IMMUNOCERV 2期临床试验的更新数据将在2024年ASTRO年会上进行口头报告，该报告将于2024年9月29日至10月2日在华盛顿特区和虚拟视觉下进行。该临床试验评估了Versamune HPV（前称PDS0101）联合化疗放射治疗，用于治疗局部晚期宫颈癌。
Details of the presentation are as follows:
演示的详细信息如下:
Date: Tuesday, October 1, 2024, 2:50-3:00 p.m. ET
Session title: SS 34 - GYN 2: Strategies and Innovations of Clinical Trials in Gynecologic Cancers
Presentation title: 298 - IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer
Presenting author: Adam Grippin, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
日期：2024年10月1日，美国东部时间下午2:50-3:00
会议议题：SS 34- GYN2：妇科癌症临床试验的策略和创新
报告主题：298- IMMUNOCERV 2期试验中结合HPV特异性T细胞免疫疗法PDS0101和化疗放疗治疗局部晚期宫颈癌
主讲人：Adam Grippin, 万博士. 米德兰德安德森癌症中心
